Page 259 - Read Online

Bosch et al. TMS for schizophrenia

schizophrenia.

DECLARATIONS
TMS for
schizophrenia
Authors’ contributions
Drafted the manuscript text, developed the intellectual
Research Better study Clinical ideas, managed the vivid discussions with the other
potential designs potential members of the research group, made the suggested
revisions, and approved the final version to be
published: P. Bosch, M. van den Noort
Heterogeneity Safety Made both intellectual and textual suggestions for
improvement, contributed to the vivid discussions
with the other members of the research group and
approved the final version to be published: S. Yeo, H.
Figure 1: Summarizing the main issues regarding TMS for Staudte, P. Barisch
schizophrenia. TMS: transcranial magnetic stimulation Made intellectual suggestions for improvement,
contributed to the vivid discussions with the other
instance, human subjects, after having been treated with members of the research group and approved the final
TMS, are known to suffer from minor complaints, such version to be published: S. Lim
as headaches, pain due to burns caused by the scalp
electrodes, local pain, etc. [4,5] , and major complaints, Financial support and sponsorship
such as mood changes, seizures, induction of hyper- None.
or hypomania, etc. [4,5] . Obviously, in an extremely
vulnerable population, such as patients suffering Conflicts of interest
from schizophrenia, those side-effects might be more There are no conflicts of interest.
prominent and may lead to even more adverse events Patient consent
and difficulties in the patient’s life.
Not applicable.
Third, as to the underlying neurobiology and possible
treatment interventions of TMS in patients with Ethics approval
schizophrenia, the clinical diagnostic issue of the Not applicable.
heterogeneity of the disorder, which is a typical
characteristic of schizophrenia, is not taken into REFERENCES
[6]
account . Although the symptoms may be common,
schizophrenia may have many different causes that 1. Kaskie RE, Ferrarelli F. Investigating the neurobiology of schizophrenia
are influenced by genetic and environmental factors, and other major psychiatric disorders with transcranial magnetic
stimulation. Schizophr Res 2017; doi: 10.1016/j.schres.2017.04.045.
resulting in a very heterogenic population of patients . 2. Dougall N, Maayan N, Soares-Weiser K, McDermott LM, McIntosh
[7]
The answers to the questions of how informative the A. Transcranial magnetic stimulation for schizophrenia. Schizophr Bull
TMS findings that have been collected on schizophrenia 2015;41:1220-22.
[1]
so far with respect to those subtypes of patient groups 3. van den Noort M, Lim S, Litscher G, Bosch P. Transcranial magnetic
with schizophrenia are and what those findings mean at stimulation for treating older patients with treatment-resistant
the individual patient level (e.g. with respect to gender depression. J Affect Disord 2017;225:278-9.
differences, interactions with individual pharmacological 4. Davis NJ. Transcranial stimulation of the developing brain: a plea for
treatments, etc.) remain unclear. 5. extreme caution. Front Hum Neurosci 2014;8:600.
Rossi S, Hallett M, Rossini PM, Pascual-Leone A; Safety of TMS
Consensus Group. Safety, ethical considerations, and application
To conclude, the critical issues mentioned above guidelines for the use of transcranial magnetic stimulation in clinical
are shown in Figure 1. If progress is to be made practice and research. Clin Neurophysiol 2009;120:2008-39.
in understanding the underlying neurobiology of 6. Arnedo J, Svrakic DM, Del Val C, Romero-Zaliz R, Hernández-Cuervo
schizophrenia and in particular, if safe TMS-based H; Molecular Genetics of Schizophrenia Consortium, Fanous AH, Pato
treatments are to be developed for patients suffering MT, Pato CN, de Erausquin GA, Cloninger CR, Zwir I. Uncovering
the hidden risk architecture of the schizophrenias: confirmation in
from this disease, these issues need to be addressed three independent genome-wide association studies. Am J Psychiatry
in future, well-designed TMS studies. The results 2015;172:139-53.
of such studies should more clearly expose the full 7. Takahashi S. Heterogeneity of schizophrenia: genetic and symptomatic
potential of using TMS in the treatment of patients with factors. Am J Med Genet B Neuropsychiatr Genet 2013;162B:648-52.
Neuroimmunology and Neuroinflammation ¦ Volume 4 ¦ December 6, 2017 259